BillionDollarBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Publishes Research Offering Evidence of Quantum Annealing’s Unrivaled Performance

D-Wave (NYSE: QBTS), a leader in quantum computing systems, software and services, and the only provider building both annealing and gate-model quantum computers, has published a peer-reviewed milestone paper showing the performance of its 5,000 qubit Advantage(TM) quantum computer is significantly faster than classical compute on an intractable class of optimization problems – 3D spin glasses. The paper also represents the largest programmable quantum simulation reported to date. A collaboration between scientists from D-Wave and Boston University, the paper titled “Quantum critical dynamics in a 5,000-qubit programmable spin glass,” was published in the peer-reviewed journal Nature today and is available here.

“This research marks a significant achievement for quantum technology, as it demonstrates a computational advantage over classical approaches for an intractable class of optimization problems,” said Dr. Alan Baratz, CEO of D-Wave. “For those seeking evidence of quantum annealing’s unrivaled performance, this work offers definitive proof.”

To view the full press release, visit https://ibn.fm/osTTx

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers — and the only company building both annealing quantum computers and gate-model quantum computers. The company’s mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. D-Wave’s technology is being used by some of the world’s most advanced organizations, including Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About BillionDollarClub

BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to millions of social media followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.

To receive SMS text alerts from BillionDollarClub, text “Billion” to 888-902-4192  (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
Editor@BillionDollarClub.com

BillionDollarClub is part of the InvestorBrandNetwork.

Lacey@GCS

Share
Published by
Lacey@GCS

Recent Posts

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures 

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with…

16 hours ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after…

16 hours ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer,…

5 days ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the…

1 week ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support…

2 weeks ago

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Carl von Halem as interim chief financial…

2 weeks ago